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Abstract
DNA damages that cause double-strand breaks (DSBs) to the chromosome are most
harmful. Subsequent choices have critical consequences for cell fate. Without repair, cells
will face certain death. Low-fidelity repair will introduce mutations that could transform
the cells, leading to carcinogenesis.
How cells make the decision is not well-understood. A single DSB can lead to
apoptosis for some cells, whereas others can repair up to 25 DSBs and survive. It has been
postulated that decision to repair DSBs is a stochastic process.
In the nucleus, DSBs elicit a cascade of signaling events that require the
recognition, protection, processing, and subsequent repair of these breaks. Repair through
homologous recombination (HR) process preserves genomic stability. The proteins
involved in HR, such as MRN, ATM, RAD51, BRCA1/BRCA2 and others have been
extensively characterized. Loss of function mutations of these proteins renders cells unable
to repair DSBs through HR and increases propensity for genomic mutagenesis.
We hypothesize that nuclear signaling events are insufficient for cellular decision
to repair DSBs through HR. In addition, the decision also relies upon the presence of prosurvival factors and subsequent activation of signaling pathways. Previous studies have
indicated that phosphorylation of proteins such as BRCA1, BRCA2, or RAD51 might play
a role in the regulation of HR activity. An example involves the phosphorylation of RAD51
by kinases downstream of phosphatidylinositol 3-kinase-related kinase (PI3K) pathway.
However, the functions of many signaling molecules in DNA damage response are still
uncertain. Using specific inhibitors of protein kinases, we aim to delineate the signaling
molecules involved during HR repair.

xiii

Using a cellular HR-reporter assay, we demonstrate that the activation of mitogenic
MAP kinase pathway has no impact on HR activity, whereas PI3K pathway is critical for
cellular decision of HR repair. Among the downstream PI3K pathways, inhibition of Akt
and PDK significantly suppresses HR repair.
Our results indicate that extracellular stimuli can regulate DNA repair process,
especially HR. These findings could have broad implications in cancer therapy and gene
therapy. Kinase inhibitors could enhance the cancer killing ability of DSB inducers such
as platinum derivatives and topoisomerase inhibitors. On the other hand, growth factors
could enhance the gene-editing efficacy through enhanced HR in techniques relying on HR
such as CRISPR.
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I.  

Introduction

Damage of the genome of a cell is inevitable and continuous since some normal cellular
processes cause DNA damage (Negritto, 2010). These damages produce several different
consequences: base lesions, intra- and inter-strand cross-link, DNA-protein cross-link, and
both single- and double-strand breaks (DSBs) (Mehta and Haber 2014). The source of
DNA damage can be subdivided into two main types – endogenous damage and exogenous
damage. Normal metabolic by-products of cells such as reactive oxygen species (ROS) can
cause endogenous oxidative DNA damage: ROS predominantly introduces DNA base
leading to single-strand break (SSB) formation, and DSBs arise following replication past
ROS-induced lesions (Woodbine et al, 2011). Exogenous damages on DNA are generally
caused by external agents such as ultraviolet radiation from the sun, ionizing radiation (IR)
and anticancer chemotherapeutic drugs. Topoisomerase inhibitors such as camptothecin
and etoposide induce the formation of SSBs and DSBs by trapping covalently linked
topoisomerase-DNA cleavage complexes. Ionizing radiations creates DNA SSBs by
producing radiolysis radicals that attack the sugar-phosphate backbone, and at high dose
of irradiation, two such nicks are generated in complementary DNA strands within one
helical turn leading to DSBs, in which the phosphate backbones of the two complementary
DNA strands are broken simultaneously (Mehta and Haber, 2014).
Though DSBs arise at a lower frequency than SSBs, they are biologically significant if
unrepaired or misrepaired because inaccurate repaired DNA can lead to mutations or
larger-scale genomic instability through the generation of dicentric or acentric
chromosomal fragments. These genome changes may have tumorigenic potential or even
can be sufficient to induce apoptosis (Jackson, 2014). Accordingly, to counteract

deleterious threats on the genome posed by DSBs, mammalian cells have evolved multiple
complex repair pathways. These includes nonhomologous end-joining (NHEJ), a process
that allows the break ends to be directly ligated without the need for a homologous template;
homologous recombination (HR), a process in which a homologous sequence acts as a
repair template; and single-strand annealing (SSA), a process initiated when a double
strand break is made between two repeated sequences oriented in the same direction
(Weinstock, 2006).
Homologous recombination (HR) is found in all forms of life, and it provides high-fidelity,
template-dependent repair or tolerance of complex DNA damages including DNA gaps,
DNA DSBs, and DNA interstrand crosslink (ICLs). HR also plays a prominent role in
faithfully duplicating the genome by providing critical support for DNA replication and
telomere maintenance (Li and Heyer, 2008). HR repairs DNA before the cell enters mitosis
(M phases). It occurs in the S and G2 phases of the cell cycle, during and shortly after DNA
replication, when sister chromatids are more readily available. A DSB in the DNA
generates region of single-stranded DNA (ssDNA) ends, which invade a homologous
chromosome to copy genetic information into the donor chromosome and serve to attract
the recombinase, either Rad51 or Dmc1, and its associated ancillary factors. ssDNA tail is
firstly bound by the Replication Protein A (RPA) protein and then displaced by RAD52
for yeast or BRCA2 for mammals, which promotes the formation and stability of Rad51 –
DNA presynaptic filaments. The ssDNA- RAD51 complex finds the intact homologous
double-stranded DNA and facilitates the exchange of identical strands and the
hybridization of complementary strands. DNA polymerase fills in the gap and moves the
displacement Loop (D-loop), forming the double Holliday junctions (dHJ). The resolution
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of a dHJ can produce crossover or non-crossover products (Guirouilh-Barbat, 2010) (Sung,
2006) (Krejci et al, 2012) (Figure.1).

(a)

Double Strand Break

(b)

End Resection
3' single-stranded DNA
(ssDNA)

(c)

ssDNA-binding replication
protein A
(RPA)

(d)

Rad51 or Dmc1
BRCA2/ Rad52
RAD51 presynaptic
filament

(e)

Accessory factors (Rad54, Rad54B
Rdh54, Hop2-Mnd1)
(f)

D-loop Formation

(g)

Holliday Junction
Formation

With crossing over

Without crossing
over

.
Figure 1.Model for double-strand break repair by homologous recombination
In mammalian cells, DSBs in the DNA generates regions of ssDNA under the control of the
RAD50/MRE11/NBS1 complex associated with CtIP. The ssDNA first interacts with the RPA
protein forming a “landing tract” for RAD52 or BRCA2, which facilitate the loading of key protein
for HR, RAD51, resulting in the formation of Rad51 presynaptic filament. The presynaptic filament
then binds duplex DNA to form the synaptic complex which searches for DNA homology in the
duplex DNA molecule. With the aid of accessory factors such as Rad54, Rad54B, Rdh54 and Hop2Mnd1, the ssDNA invades the homologous region in the duplex to form D-loop. The Holliday
junctions are then formed. The directional resolution of the Holliday junctions occurs by crossing
over independent or crossing over dependent mechanisms. Adapted from Guirouilh-Barbat,
Wilhelm & Lope, 2010.
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Upon the formation of DNA-damage, sensors detect DNA lesions and subsequently
activate apical ataxia telangiectasia mutated (ATM) and ATM Rad3-related (ATR) kinases
and their recruitment to the DNA-damage sites, the process called DNA-damage response
(DDR) signaling. Checkpoint kinase 1 (CHK1) is one of the key downstream molecules.
In response to DNA damage, it is phosphorylated by ATR kinase at Ser345 primarily to
arrest the cell cycle in S ant at G2/M phases to promote DNA repair before cell division.
Meanwhile, CHK1 can also be phosphorylated by other kinases such as PKB/AKT and
MAPKAPK at different sites. When activated, CHK1 phosphorylates a variety of
intracellular substrate proteins, including the central molecule in HR pathway, the
recombinase Rad51 (Narayanaswamy. et al, 2016).
As shown in Figure 1, HR is catalyzed by a class of enzyme known as recombinases, either
Rad51 or Dmc1, the activity of which is tightly regulated by other factors (Sung and Klein,
2006). For human HR, human Rad51 (hRad51) is a key protein, which forms a helical
nucleoprotein filament on RPA bound ssDNA and such presynaptic filament performs
several of the most basic steps of HR: a search for homologous double-stranded DNA
(dsDNA) and DNA strand exchange (Bugreev and Mazin, 2004). For eukaryotic orthologs,
in the presence of ATP Rad51 forms a helical filament on DNA because the activities for
DNA-binding and DNA strand exchange require the bound of ATP. Though ATP
hydrolysis plays crucial functions in promoting the disassembly of the filament for
bacterial RecA protein, the hydrolysis process is not required for eukaryotic orthologs. (Li,
2007) (Bugreev and Mazin, 2004). Though the role of the ATPase activity of Rad51 protein
remains obscure, it is evident that in response to DNA damage, Rad51 protein catalyzes
the annealing of resected DNA ends to homologous DNA in the presence of ATP. The
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phosphorylation of Rad51 on site Ser192 is mediated by the DNA-damage- responsive
protein kinase Mec1. Thus, Rad51 phosphorylation on Ser192 is crucial for Rad51 function,
which provides a potential mechanism for how Mec1-mediated phosphorylation of this site
could influence HR (Flott et al., 2011).
Moreover, the mechanism of Rad51 protein activation by Ca2+ significantly stimulates
DNA strand exchange activity of Rad51 protein. The Rad51-ATP-ssDNA filament
becomes quickly converted to an inactive Rad51-ADP-ssDNA form because of the
relatively rapid ATP hydrolysis and slow dissociation of ADP. To restore the active Rad51ATP-ssDNA filament, Ca2+ ion exerts its stimulatory effect to modulate the ATPase
activity of Rad51 protein by slowing down the ATP hydrolysis rate (Bugreev and Mazin,
2004). As a ubiquitous second messenger, calcium functions in wide-ranging physiological
and biochemical roles including cell proliferation and components of cytoskeleton. In
addition, calcium ion plays important roles in the cellular signaling pathway, especially for
phospholipase C (PLC). Diacylglycerol (DAG) and inositol trisphosphate (IP3) produced
by PLC catalyzed reaction are two second messengers that function as substrates for
synthesis of other important signaling molecules. While DAG remains bound to the
membrane, IP3 is released as a soluble structure that diffuses through the cytosol to bind
IP3 receptors, which causes the cytosolic concentration of calcium to increase and cascade
of intracellular changes and activity. For example, calcium and DAG activate protein
kinase C (PKC) to phosphorylate other molecules to lead to altered cellular activity. These
findings provide a potential mechanism for the way in which PLC-mediated calcium
signaling pathway could influence HR either.

5

Mechanisms of regulation of HR are not completely understood yet. Based on the current
studies, it has been suggested that both Mec1-mediated phosphorylation of Rad51 on
Ser192 and PLC-mediated calcium signaling pathway are possible to regulators of Rad51,
which subsequently might influence HR process. There are two potential phosphorylation
sites, Ser192 and Thr197 on Rad51. Ser192 is reported to be phosphorylated by Mec1
kinase. However, it is still unknown whether other kinases can phosphorylate Ser192
and/or Thr197 on Rad51 to regulate its activity. In addition to Rad51 as a key protein, the
HR machinery is known to involve other critical proteins, such as the highly conserved
MRN complex, whose core contains the proteins Mre11, Rad51 and Nbs1, which are
required for ATM activation and consequently for timely activation of ATM-mediated
pathways (Uziel et al, 2003). Thus, the regulation of ATM protein kinase might also
influence HR. Furthermore, it remains to be determined whether other protein kinases,
distinct from Mec1, ATM and PKC, also play significant role in modulating the HR
machinery, in relationship to cell survival and apoptosis and cell cycle progression.
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II.  

Background

A.   DNA Replication Machinery
Each parental strand serves as a template for the synthesis of a new complementary
daughter strand in DNA replication by a semiconservative process. As a central enzyme,
DNA polymerase catalyzes the joining of deoxyribonucleoside 5’-triphosphates (dNTPs)
to form the growing DNA chain. Proofreading mechanisms are involved in maintaining
that the accuracy of replication is compatible with the low frequency of errors that is
required for cell reproduction. DNA replication machinery has three major steps:
A.1.   Initiation
A trans-acting ‘initiator’ factor starts the process of replication by directing assembly and
loading of the replicative machinery onto particular genomic loci called origin of
replication in both space and time. In short, replication initiation includes four steps.
1)During the G1 phase of the cell cycle, the start sites are demarcated by the Origin
Recognition Complex (ORC) and the cell division cycle 6 (Cdc6) helicase-loader. 2) To
form the pre-replication complex (pre-RC) at the origins of replication, with chromatin
licensing and DNA replication factor 1 (Cdt1), an origin bound ORC•Cdc6 complex
facilitates the reiterative recruitment of an inactive form of the replicative helicase,
minichromosome maintenance proteins (MCM2-7). Cyclin-dependent kinase 2 (CDK) and
Dbf4-dependent kinase (DDK) are used to activate the pre-RC complex, which then helps
transition the pre-RC to the initiation complex prior to the initiation of DNA replication
and leads to replisome assembly and origin formation. 3) In S-phase, other initiation factors
such as cell division cycle 45 (Cdc45) and GINS are recruited. The helicase is activated to
drive fork progression as the formation of the pre-initiation complex (pre-IC), and single-
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stranded DNA-bound Cdc45•MCM2-7•GINS(CMG) complex. The loading of Cdc45 onto
chromatin allows the assembly of other various replication proteins such as DNA
polymerase α, replication protein A (RPA) and proliferating cell nuclear antigen (PCNA)
onto chromatin. GINS complex is essential for the interaction of MCM and Cdc45 at the
origins of replication. Cdt1 is degraded in a PCNA-dependent manner. Its specialized PIP
motifs, which has the greater affinity for PCNA and is responsible for making the protein
a substrate for E3 ubiquitin ligase CRL4Cdt2, is bound to a PCNA ring. CRL4Cdt2 facilitates
the poly-ubiquitylation of Cdt1 leading to its degradation. Therefore, Cdt1 is not available
to re-license origins (Boehm, 2016) in S-phase. 4) A bidirectional replication fork is
generated, and DNA is unwound to expose template DNA (Parker, 2017).

8

origin
G1 Phase

ORC
Origin Selection

Cdc6

Cdc6
G1 Phase

ORCs

MCM2-7

2x helicase
loading

Cdt1

Cdc6
ORCs

G1 Phase

Pre-RC Double Hexamer
CDKs

DDKs

P

P

P
ORCs

Pre- S Phase

Cdc45
GINS

P

Cdc6

Pre-IC Cdc45. MCM2-7. GINS
P

S Phase

P
ORCs

Replisome
components

bi-Directional Replication
Fork

GINS
P
Cdc45

S Phase

P

Cdc45

GINS

P
ORCs

Figure 2. Mechanistic outline of DNA replication initiation in eukaryotes.
1)   The starts sites are demarcated by the ORC and Cdc6
2)   An inactive form of the replicative helicase MCM2-7 is loaded reiteratively to replication
origins by ORC•Cdc6 and the Cdt1 chaperone. The pre-RC complex is formed
3)   CDK/DDK-dependent phosphorylation of pre-replicative proteins. Cdc6 and Cdt1 are removed
from the nucleus. GINS and Cdc45 are loaded onto replication origins and the helicase is then
activated by the formation of pre-IC complex.
4)   DNA is unwound. Generation of a bidirectional replication fork. Replication is initiated
“P” represents phosphorylation.
Adapted from Parker, 2017.
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A.2.  

Elongation

The cells enter the S phase of the cell cycle upon the formation of the initiation complex.
The initiation complex interacts with a constellation of other proteins including DNA
polymerases and becomes a replisome. The parental duplex DNA is unwound by replisome
into a two single-stranded DNA template or the replication fork, which is responsible for
the replication of the entire genomic DNA. The base pairing and chain formation that move
along single-stranded DNA are catalyzed by DNA polymerases. The nascent DNA strand
is extended by reading the template strand and the incorporation of the proper nucleotides.
These activated free deoxyribonucleotide triphosphates (dNTPs) are added to the exposed
3’-hydroxyl group on the last incorporated nucleotide. Though DNA replication occurs in
the opposite directions in the two new strands, leading and lagging strands, at the
replication fork, all DNA polymerases synthesize DNA in the 5’ to 3’ direction. The PCNA,
DNA sliding clamps for eukaryotes, is loaded onto primer-template junctions site via
replication factor c (RFC) complex and associates with the polymerases to promote their
processivity.

10

Leading

Lagging

Figure 3.DNA replication at Replication Fork. Adapted from Burgers, 2017.

On the leading strand synthesis, before extending further with DNA, DNA polymerase α
(Polα) first synthesizes an RNA primer. Polymerase ε then takes over and adds nucleotides
to the template strand continuously (Figure 3).
Synthesis on the lagging strand is initiated with the formation of the primer by Polα, and
is followed by loading of PCNA RFC, which subsequently recruits polymerase δ (Polδ)
extending the primer to complete the short sequences called Okazaki fragment. The RNA
primer is removed by strand displacement; namely, Polδ displaces the 5’end for the
previous Okazaki fragment, which contains the RNA primer and a small segment of DNA.
Fen1 then cleaves the RNA-DNA single strand flap generated by Polδ and leaves the nick
between two Okazaki fragments, which is sealed by DNA ligase I (Figure 3).
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A.3.  

Termination

When two replication forks meet on the same stretch of DNA, the termination of DNA
replication occurs. During the process, the forks converge until all intervening DNA is
unwound and any remaining gaps are filled and ligated. Since the eukaryotic cells contain
a circular chromosome, the two DNA molecules remain linked together after the replication
of the entire molecule. Type II topoisomerase is used to remove any remaining catenanes.
The replication proteins are unloaded (Dewar, 2017).
B.   Maintenance High Fidelity for DNA Replication
The balance between incorrect and correct DNA synthesis has significant biological
consequence. DNA replication machinery faithfully replicates the genomes despite facing
constant challenges from cellular metabolism and the external environment. The incorrect
nucleotides, if not corrected, could have dire consequence. The high fidelity of DNA
replication is maintained through three fundamental mechanisms. The high-fidelity of
replicative DNA polymerases, proof-reading abilities of exonuclease domains of
polymerases, and mismatch repair. The first two properties reside within DNA polymerases
δ and ε, contributing to the error rate of the replication machinery in the range of 10-7 to
10-8. The MMR improves the fidelity about two orders of magnitude. The three significant
determinants for replication fidelity (Kunkel, 2004) are further summarized below.
B.(a).  

Proofreading

Upon misincorporation of an incorrect nucleotide, two mechanisms can lead to the excision
of the wrong nucleotide. The replicative polymerase that inserts a wrong nucleotide
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dissociates, which allows another protein with intrinsic 3’ → 5’ proofreading exonuclease
activities to excise 90-99.9% of incorrectly incorporated mononucleotides and then replace
with the correct nucleotide to continue synthesis by the replicative DNA polymerase.
Meanwhile, genome stability requires DNA synthesis to fill gaps created when lesions are
excised. Gap filling process during mismatch repair, nucleotide excision repair, and long
patch base excision repair (BER) is performed the intrinsic proofreading activities of T4
Pol, Pol δ, Pol ε and T7 Pol polymerases (Kunkel, 2004).
B.(b).  

High Fidelity of DNA Replication Polymerases

Nucleotide selection step is another major determinant for overall fidelity for DNA
polymerases. The ability to insert the correct nucleotide and requires several
conformational changes to achieve stabilization of the transition state (Kunkel, 2004). The
DNA polymerase first forms a complex with DNA, a nucleotide and two metal ions at the
active site of the enzyme. The binding process and the stabilization of the incoming
nucleotide are accomplished in the nucleotide binding pocket, which includes the
interactions between the nucleotide and the template bases, the polymerase active-site
residues, the fingers domain of polymerase, the metal ions, and the 3’-terminal hydroxyl
group of the primer strand. A dNTP-induced conformational change within the polymerase
fulfills these interactions, which is referred to as an induced fit mechanism. When an
incorrect nucleotide is bound within the nucleotide binding pocket, the phosphodiester
bond will not be formed due to the lack of proper geometry within the active site. Therefore,
the incorrect nucleotide will leave the pocket. The nucleotide selection fidelities of Pol α,
Pol δ, and Pol ε are around one error per 104 – 105 incorporated nucleotides (Ganai, 2016).
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B.(c).  

Mismatch Repair

Base-base mismatch and insertion/deletion (ID) misparis generally arise during DNA
replication. DNA mismatch repair (MMR) is then used to correct DNA mismatches and
reduces the number of replication – associated errors, thereby prevents the occurrence of
mutations in dividing cells. In prokaryotes, the hemi-methylated dGATC sites are used to
discriminate daughter and template strands since the daughter strand is transiently
unmethylated and hMutSα preferentially recognizes base-base mismatches and ID
mispairs of 1 or 2 nucleotides while hMutSβ recognizes longer ID mispairs. Such strandspecific nick generated via hMutSα or hMutSβ and hemi-methylated dGATC creates a
starting point for excision of the mispaired base. In human MMR, since the new DNA
strand has a primer terminus that PCNA and RFC are bound to, the interaction between
hMutSα/ hMutLα with PCNA/RFC also provides the means for identifying the newly –
made strand. The hMutLα endonuclease is activated to cleaves the new strand after binding
to RFC and PCNA. Exo 1, a 5’ to 3’ exonuclease is recruited and cleaves the DNA strand
from the 5’end to the nick made by hMutLα to remove the mismatch. The gap is filled and
sealed with Pol δ and DNA ligase (Li, 2007).
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Figure 4. Mechanisms for MMR
1)   hMutSα/ hMutLα binds to the Mismatches
2)   Communication between hMutSα/ hMutLα and RFC and PCNA at the primer terminus
DNA chain
3)   The hMutLα endonuclease is then activated
4)   Exo 1 is recruited and cleaves the DNA strand from the 5’end to the nick made by
hMutLα
5)   (Not Shown) Pol δ and DNA ligase fill in and seal the gap.
Adapted from Mismatch Repair, ACSU. Buffalo.edu Accessed March 24, 2019

C.   Source of DNA Damage
DNA insults result from either cellular metabolic process (endogenous sources), which
includes hydrolysis, oxidation, alkylation, and mismatch of DNA bases, or environmental
factors (exogenous sources), which contains ionizing radiation (IR), ultraviolet (UV)
radiation, and various chemicals agents (Hakem, 2008). CpG to TpG transition mutation is
generated by the spontaneous deamination of 5’- methylcytosine, which converts C to T
and is recognized by thymine DNA glycosylase (TDG). Guanine is oxidized by ROS to
form 8-oxoG, which can pair with adenine and then generate G to T mutations. DNA
polymerase errors induce MMR, and failure to complete MMR will cause incorrect base
substitutions. Cyclobutane pyrimidine dimers are generated by exposure to UV light. The
dimers are recognized by nucleotide excision repair (NER) factors and excised by XPG
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and XPF flap endonucleases. The G to T transition mutations at CC dinucleotides are
caused by the failure to complete NER (Tubbs, 2017).
D.   DNA Damage Repair Mechanisms
D.(a).  

Single-Strand Break

SSBs, which are discontinuities in on strand of DNA double helix due to the loss of a single
nucleotide and damaged 5’- and / or 3’- termini at the site of the break, are the most
common types of DNA damage. These arise in cells at a frequency of tens of thousands
per cell per day. These damages are directly caused by intracellular metabolites and
spontaneous DNA decay and will cause a severe threat to genetic stability and cell survival
if not repaired appropriately. Chromosomal single-strand break repair (SSBR) is a rapid
and efficient process. SSBs are detected by the binding and activation of poly(ADP-ribose)
polymerase 1 (PARP1), which promotes rapid accumulation of downstream repair factors.
PARP1 accelerates SSBR in multiple possible ways. Firstly, it promotes the focal
accumulation or stability of SSBR protein complexes at chromosomal SBs through
interaction with dedicated pADPr-binding motifs. Furthermore, PARP1 regulates
chromatin structure since histone proteins are targets for poly(ADP-ribosylation).
Therefore, pADPr synthesis can disrupt nucleosomes and then regulate higher-order
chromatin compaction. Moreover, PARP is suggested to promote DNA gap filling during
long-patch repair and to generate ATP for the DNA ligation step. Finally, since PARP1 is
a transcriptional regulator, so it might accelerate SSBR rates by affecting the level of SSBR
proteins (Caldecott, 2008).
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D.(b).  

Double-Strand Break

DSBs are lesions formed when both strands of the DNA duplex are broken, which are
highly toxic. DSB is a major driver in carcinogenesis due to its repair or mis-repair that
could cause genome rearrangements. DSBs are also related to developmental,
immunological, and neurological disorders as well as cell death. Though exogenous agents
such as IR and chemicals can cause DSB, DNA replication is a major source of DSB. When
encounter unrepaired DNA lesions, the forks will stall and then collapse, leading to DSBs.
A one-ended DSB also forms when replication fork encounters a nick in the template DNA.
A single unrepaired DSB could lead to cell death. Organisms have evolved a range of DSB
repair mechanisms to prevent these severe consequences and to support a critical role in
maintaining genetic stability. HR and NHEJ are two major DSB repair pathways
(Chapman, 2012).

D.(b).(1)   Nonhomologous end-joining
Though it is dominant in G0/G1 phase, NHEJ occurs throughout the cell cycle, while HR
only functions in late S/G2 phase since the full set of sister chromatid is generated during
the S phase of interphase. NHEJ is initiated by Ku70/Ku80 protein complex (Ku
heterodimer), which recognizes and binds DSBs ending, and DNA-bound Ku protects ends
from nuclease digestion but does not stop ataxia telangiectasia mutated (ATM) activation
or signaling. DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is then
recruited by DNA-bound Ku, which binds to broken ends and phosphorylates itself and
other targets including Artemis, a nuclease that trims the DNA ends, to generate the DNAPK complex and activate the activity of DNA-PK. This kinase activity facilitates
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recruitment of the DNA ligase complex including DNA ligase IV, X-ray cross complementing Group 4 (XRCC4) and XRCC4-like factor (XLF)/cernunnos, which
contribute to end processing and seal the DNA break (Kakarougkas, 2014).
DSB
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DNA-PKcs

DNA-PKcs

Ku

DNA-PKcs

DNA-PKcs

Ku

Artemis

Ku

Artemis

DNA-PKcs

DNA-PKcs

Ku

Ligase IV
XRCC4/

Artemis XLF
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Figure 5. Mechanism for NHEJ Repair
1)   DNA End-binding and Bridging: Initiated by the recognition and binding of the
Ku70/Ku80 heterodimer to the broken DNA ends, which then recruits the catalytic subunit
of DNA-PKcs
2)   Terminal Ending Process: DNA-PKcs phosphorylates itself and bound Artemis protein,
and the Artemis/DNA-PKcs complex have nuclease activity to cleave 5’ and 3’ DNA
overhangs
3)   Ligation: DNA ligase IV, XRCC4 and XLF carries the ligation step
Adapted from Davis, 2013
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D.(b).(2)   Homologous Recombination
As depicted in Figure 1, HR uses an undamaged template to re-generate any sequence of
information lost at the DSB site. 5’ to 3’ end resection generates a 3’ended single-strand
region, which initiates the mechanism of HR. RPA binds to the ssDNA tail rapidly to
prevent the formation of secondary structures, and it is displaced by RAD51 subsequently
via a Breast Cancer Associated Gene 2 (BRCA2) – dependent process. RAD51 promotes
invasion onto the undamaged template and strand displacement to induce D-loop formation,
which is used to generate a Holliday junction and a heteroduplex molecule. Finally, the
resolution of Holliday junctions produces either cross-over or non-cross-over products
depending on the direction of resolution and completes the HR process (Kakarougkas,
2014).
E.   Coupling of Homologous Recombination and Cell-cycle Checkpoints

Figure 6. Cell Cycle Control. Adapted from Cancer Genetics, CuboCube.

Cell-cycle checkpoints are critical control mechanisms in eukaryotic cells to establish order
and timing of cell cycle progression, to ensure complete genome duplication even in the
faces of damage stress, and proper division of cells. The cell cycle encompasses two major
phases including interphase, which contains G1 (gap phase 1), S (DNA synthesis) and G2
(Gap phase 2), and M (mitosis) phase (Figure 6). Cyclin-dependent kinases (CDKs)
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function as the central regulators in cell cycle progression. These serine/threonine kinases
that phosphorylate key substrates to promote DNA synthesis and mitotic progression,
thereby drive cell cycle progression (Barnum, 2014). There exist two essential checkpoints
in the cell cycle to ensure the integrity of daughter cells, G1/S checkpoint, and the G2/M
checkpoint.
E.(i).   G1/S checkpoint
The G1/S checkpoint is used to control the commitment of eukaryotic cells to transition
through the G1 phase to enter the S phase, during which DNA replication occurs, therefore,
the proliferation of irreparably damaged cells is prevented. In higher organisms, the G1/S
checkpoint is regulated by p53, which is a tumor suppressor and transcription factions, and
its down-regulation plays a significant role in tumorigenesis. p53 and its negative
regulatory protein, Mouse double minute 2 homolog (MDM2) or E3 ubiquitin-protein
ligase Mdm2, are phosphorylated directly or indirectly on N – terminal serine-15 by
damage response kinase ATR, ATM, and DNA-PKcs to enhance p53 stability and DNA
binding activity. ATM kinase targets to DSB by interacting protein Mre11-Rad50-Nbs1
(MRN) and the interacting protein Ku70-Ku80 complex are used for DNA-PKcs. The
activated p53 is stabilized through protein from MDM2, and it regulates transcription of
CDK inhibitor p21Waf1/Cip1. Therefore, G1 CDKs are inhibited, and G1/S checkpoint is
arrested, to enable repair of DNA damage before DNA replication (Barnum, 2014)
(Deckbar, 2010).
DNA damage checkpoints are also controlled by checkpoint kinase Chk1. Two master
checkpoint kinases, the ATM (ataxia-telangiectasia mutated) and ATR (ataxia
telangiectasia mutated and rad3-related), are activated by DSBs in mammalian cells. ATM
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and ATR kinases phosphorylate and activate the transducer kinases Chk2 and Chk1, which
are activated by all known forms of DNA damage, restricted to post-replicative lesions,
and it is more efficient in S- and G2-phase.
After phosphorylated by ATR, BRCT domain (for BRCA1 carboxyl terminus) mediator
proteins are recruited and serve for the recruitment of Chk1, which is released to maintain
the mitotic CDK Cdc2 in its Y15 phosphorylated and inactive state. The phosphatase
Cdc25A, which regulates inhibitory phosphorylation of Cdk1/Cdk2, is phosphorylated by
Chk1. The activity of Cdc25 is then decreased. Therefore, the activated pathway for G1 - S
is arrested due to the inhibition of Cdc25A – mediated activation of cyclin E – Cdk2
(Barnum, 2014) (Deckbar, 2010).
E.(ii).   G2/M checkpoint
Upon the detection of DNA damage, the G2/M checkpoint prevents cells from entering
mitosis and provides an opportunity for repair. Cdk1 is the master regulatory kinase that
controls cell entry into mitosis. In G2 phase, cyclin B is kept in the cytoplasm by binding
to nuclear export CRM1. When cells approach the G2/M boundary, cyclin B is
phosphorylated to prevent its binding to and consequently stops being exported. The
accumulation of cyclin B in the nucleus induces entry into mitosis. Similar to G1/S
checkpoint, p53-independent pathways involving ATM, ATR-dependent activation of
Chk1 and Chk2 can rapidly arrest G2 – M phases by phosphorylating Cdc25 and
stimulating its binding to 14-3-3 proteins to anchor it in the cytoplasm (Stark, 2007).
Moreover, p53 is also required for prolonged G2 arrest since human Cdc25 gene is a target
for p53-dependent transcriptional repression (Clair, 2004).
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To survive the inevitable adverse challenges by extrinsic and intrinsic stresses and pass on
intact genetic information to subsequent generations, cells have developed a highly
organized and coordinated response, DNA damage response (DDR), to ameliorate
genotoxic stress. DDR demands cell’s ability in sensing and signaling problem in its DNA,
arresting cell-cycle progression and activating appropriate DNA repair mechanisms to
eliminate cells with unrepairable genomes. Like other classical cell signaling pathways
such as receptor tyrosine kinase cascade, DDR signaling pathway regulates and coordinates
the cellular response to DNA damage by using signal sensors, transducers, and effectors.
While ligands binding to receptors activate classical signaling pathway, the DDR signaling
pathway is activated by aberrant DNA structure. These structures could originate from
nucleotide base damage, DNA strand breaks, and replication stress. The sensors involved
in the DDR signaling pathway are proteins that can recognize DSBs or stalled/stressed
DNA replication forks. The transducers include ATM, ATR, and their downstream kinases
that can phosphorylate effectors (Marechal, 2013).
In mammalian cells, the ATM, ATR and DNA-PKcs kinases are the three most upstream
DDR kinases. The catalytic kinase domains are located at the C-terminus, exhibit
homology to the phosphatidylinositol 3 (PI3) family of lipid kinases (PI3Ks), and thereby
belongs to PI3K-like protein kinases (PIKKs) family (Figure 7). As mentioned before,
DNA-PKcs play a role primarily in the NHEJ pathway, while ATM and ATR activate the
second wave of phosphorylation through the activation of Chk1, Chk2 and MK2 protein
kinases in DSBs. These three kinases are all serine/threonine-directed and have a
preference of Ser/Thr – Glu motifs, which phosphorylate hundreds of proteins in response
to DNA damage (Paull, 2015).
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Figure 7. Structural Basis of PIKKs (ATM, DNA-PKcs, and ATR) Functional
Diversity
PIKKs share a similar domain organization. The kinase domains are located near carboxyl-termini
and contain the catalytic loops of Class-I PI3K and therefore they are categorized separately from
the classic protein kinases. The kinase domains are flanked by conserved FRAP-ATM-TRRAP
(FAT) and FAT carboxy-terminal (FATC) domains; these two domains are essential for ATR and
ATM activation and mutations will hamper their kinase activity. In addition, PIKK contains PIKKregulatory domain (PRD), and their N – terminus bears numerous α-helical Huntingtin, elongation
factor 3, protein phosphatase 2A, TOR1 (HEAT) repeat motifs, which act as a scaffold to mediate
the interactions of ATM and ATR with proteins that regulate their catalytic activity. Under nonstress conditions, ATM exists as dimers or oligomers and it is released in monomeric form in
response to DNA damage. ATR forms a heterodimer with its obligatory partner ATR-interacting
protein (ATRIP). In response to DNA damage, ATR and ATM are autophosphorylated near their
FAT domains (Marechal, 2013) (Awasthi, 2015).
Adapted from Marechal, 2013, Figure 2.

E.(iii).   Ataxia Telangiectasia mutated and rad3-related (ATR) Kinase
As a master regulator of DNA damage signaling, upon activation in S-phase, ATR can
suppress firing of replication origins and restrains DNA synthesis; while activated in G2-
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phase, it can promote the G2/M cell-cycle arrest (Buisson, 2017). Not only required for
the full checkpoint response to DSBs, but ATR also responds to a broad spectrum of other
DNA damages, especially those interfering with DNA replication. ATR is recruited to
DSBs via RPA-coated single-stranded DNA (RPA-ssDNA), which is generated by the
nuclease-mediated resection of DSBs and this ssDNA is also necessary for the HR pathway
(Shiotani, 2009). ATR regulates DSB repair in homologous recombination. Most recent
studies from Buisson suggest that ATR regulates HR through controlling the S59-S64
“phosphorylation switch. HR occurs in two consecutive phases: the resection and ATR
activates driven by high CDK activity in the first, and ATR then suppresses CDKs and
phosphorylates HR substrates in the second. Since this CDK – to – ATR switch is necessary
for optimal BRCA1 – PALB2 interaction and other possible HR events, therefore, ATR
can promote HR by phosphorylating HR substrates and inhibiting CDKs, directly coupling
the checkpoint to HR (Buisson, 2017).
ATR in Homologous Recombination – Mediated Repair
BRCA1 associates and co-localizes with RAD51 in nuclear foci in mitotic cells, and it acts
as a recombination mediator or co-mediator to promote ssDNA resection via interaction
with CtIP, those observations indicate that BRCA1 functions in HR repair (Zhang, 2013).
ATR promotes HR-mediated repair via phosphorylating PALB2 and enhancing its
localization to DNA lesions via interaction with BRCA1 after DNA damage. Additionally,
BRCA1 phosphorylation and its interaction with TOPBP1 are mediated by ATR to
promote HR since BRCA1 is stabilized at lesions during S-phase (Kim, 2018).
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E.(iv).   Ataxia – telangiectasia mutated (ATM)
ATM kinase is critical for the initial response and the subsequent ATR activation, and it is
primarily activated by DSBs and coordinates checkpoint activation and DNA repair in
response to DSBs. The inactive dimeric ATM is monomerized into active monomers by
MRN complex, which is highly conserved and plays critical roles in DSB in all organisms.
MRN complex also acts as a cofactor for ATM catalytic activity that promotes the activity
of ATM in physiological conditions in which magnesium is the primary cation. Thus, the
ATM kinase is activated via the MRN complex (Paull, 2015). After the initial activation
by DSBs, ATM executes specific functions around the breaks via chromatin-mediated
mechanisms involving H2AX, Mdc1, and other proteins (Shiotani, 2009) (Figure 7).
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Figure 8. Activation of ATM by DSBs. 1] The DNA ends and chromatin are recognized by
ATM. The MRN complex functions as a sensor of DNA ends and direct activator of the ATM
kinase that converts inactive dimeric ATM to active monomer. Meanwhile, autophosphorylation
of ATM occurs at residue Ser1981 coincides with the activation of ATM monomerization. 2] The
activated ATM phosphorylates substrates including Chk2 and p53. H2AX in flanking nucleosomes
is also phosphorylated. 3] Mediator of DNA damage checkpoint protein 1 (Mdc1) recognizes
phosphorylated H2AX (γH2AX) to trigger a feed-forward loop that spreads activated ATM and
γH2AX over large chromatin domains 4] (Marechal, 2013).
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Activation of DSB-Signaling Cascade and p53 by ATM
Figure 8 illustrates that the activated ATM can phosphorylate substrates including Chk2
and p53, which then activates the DSB-signaling cascade and the activity of p53 protein.
Figure 9 provides more details in ATM serine/threonine kinase and the functions of ATMdependent signaling events in response to DNA damage.

Figure 9. ATM-Mediated three types of Response to DNA Double Strand Breaks.
Adapted from ATM serine/threonine kinase, Wikipedia.

ATM phosphorylates and activates hundreds of substrates for DSB-signaling cascade, and
the most typical and well-characterized example is the Chk2 kinase. The Chk2 protein
contains a Ser/Thr – Glu cluster domains including five Ser-Glu and two Thr-Glu motifs
that satisfy the primary substrate motif for ATM kinase. Following DNA damage, the
inactive monomers of Chk2 are phosphorylated by ATM directly at residue Thr68, a
consensus site in the SCD domain and undergo dimerization, and autophosphorylation of
Ser516 within the kinase domain, which is required for full kinase activation. Cdc25A and
Cdc25C, two members from the Cdc25 phosphatase family, promote cell cycle progression
by activating Cdk2 and Cdk1 via dephosphorylation of inhibitory phosphorylation at Thr14
and Tyr15. Chk2 counters these actions by phosphorylating and inactivating Cdc25A, and
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thus prevents G1/S transition. Besides, Chk2 phosphorylation creates a binding site for 143-3 proteins at Ser216 in Cdc25C, which causes the persistent cytoplasmic Cdc25C
localization and thus prevents the G2/M transition since the Cdk1/Cyclin B complex cannot
be activated (Ahn, 2004).
Secondly, a portion of (~20%) IR-induced DSBs are repaired by a pathway requiring ATM
as MRN-dependent ATM activation in order to trigger phosphorylation of DNA-PKcs to
promote Artemis recruitment and activation. ATM promotes HR either through stimulating
DNA-end resection, which is a crucial determinant of choice for DSB repair pathway.
DSB-end processing to produce tracts of ssDNA is essential to invade another DNA
molecule after binding by the recombinase RAD51(Blackford, 2017)37. Mechanistically,
ATM phosphorylates the MRN-interacting protein CtIP (C-terminal binding protein 1
interacting protein), which promotes the resection of DSBs and are essential for meiotic
recombination (Makharashvili, 2015).
Finally, in response to DNA damage, the tumor suppressor p53 is stabilized for the
activation of a transcriptional program that can cause cell-cycle arrest in G1 phase,
senescence, or apoptosis. ATM phosphorylates p53 on multiple sites that include S15. The
phosphorylation of S15 inhibits the interaction of p53 with the ubiquitin ligase MDM2,
resulting in the stabilization and activation of p53, which promotes the transcription and
translation of Cdk inhibitor p21 in response to DSBs. The increased p21 level helps to keep
Cdk activity low to maintain longer cell cycle arrest in G1 phase (Blackford, 2017).
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F.   Overall Goal of the Study
Experiments in this thesis are to explore and test the thesis that extracellular environment
affects the cellular decision for DNA repair, especially homologous recombination repairs
of DSBs. The link between the extracellular signal to HR is examined by using specific
inhibitors for cytoplasmic kinases. DSBR reporter assay is developed to detect HR induced
by DSB with DR-GFP reporter. DR-GFP substrate is used to monitor HR. It contains two
differentially mutated green fluorescent protein (GFP) genes, which are oriented as direct
repeats (DR): the recognition site for the rare-cutting I-SceI endonuclease on the upstream
repeat and 5’ and 3’ truncated GFP fragment on the downstream repeat. Transient
expression of I-SceI causes DSB in the upstream GFP gene and HR to repair DSB finally
results in GFP+ cells, which can be quantified by flow cytometry (Nakanishi et al., 2011)15.
In this thesis, I hypothesize that nuclear signaling events are insufficient for the cellular
decision to repair DSBs through HR. Besides, the decision also relies upon the presence of
pro-survival factors and subsequent activation of signaling pathways. Several previous
studies have indicated that the phosphorylation of proteins including BRCA1, BRCA2, or
RAD51 might play a role in the regulation of HR activity. However, the functions of many
signaling molecules in DNA damage response are still uncertain. Using specific inhibitors
of protein kinases, I aim to delineate the signaling molecules involved in HR repair
pathway.
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III.  

Material and Methodology

1.   Cell Culture
Human kidney cell line 293T/HEK 293T (ATCC CRL-11269TM) and 293T – DR, which
®

are 293T cells stably transfected with pDRGFP plasmid via LipofectamineTM 3000
Transfection Reagent Invitrogen (ThermoFisher Scientific), were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) and supplemented with 10% heat-inactivated fetal
bovine serum(FBS) (Lonza, Waltham, MD), 2mM L-glutamine and 1X Penicillin –
Streptomycin in humidified incubator in 37℃, 5% CO2 and 95% humidity. These reagents
were purchased from Invitrogen (Waltham, MA).
2.   MTT Assay
80% - 90% confluent cells were enzymatically detached by Trypsin-EDTA solution
(Sigma-Aldrich) and counted by hemocytometer. In general, 1000 cells/100µl/well were
seeded in 96 – wells plates for 24 hours before any treatment. After the addition of several
kinase inhibitors to the desired concentrations, the cells were incubated in the CO2
incubator. After 72hrs exposure, 20 µl of 5mg/ml 1-(4,5-Dimethylthiazol-2-yl)-3,5diphenylformazan (MTT) stock solution was added and MTT reactions proceeded in the
dark for 4hr. 100µl of 10% SDS in 0.01M HCl (Septisetyani, 2014) was subsequently
added to dissolve formazan crystals. To accelerate the dissolution of crystals, the plates
were then shaken on a nutating platform and incubated in the dark overnight. The
absorbance was read at 450nm and 595nm set as reference wavelength on a Multi-Mode
Microplate Reader (FilterMax F5). All doses were set up in triplicate and experiments were
repeated in three times to yield consistent and reproductive results.
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2.2. IC50 Determination
Seven concentrations of each kinase inhibitors were used in this experiment. Similar to
above MTT assay, 293T cells were seeded in 96-well plates at a density of 1000
cells/100µl/well 24hrs before treatment with different inhibitors at a specific concentration
range. After 72hrs exposure, the cells were analyzed via MTT cell proliferation assay. The
dose - response curves for the determination of IC50 values were generated in GraphPad
Prism 7 (GraphPad Software Inc. La Jolla, CA, USA).
Table 1. Concentration Range for Each Kinase Inhibitor
PI3K: Buparlisib (BKM120)
0.1µM – 2.0µM (Netland, 2016)42
Mek: GSK1120212
0.5nM – 5.0nM (Gilmartin, 2011)43
Akt: Afuresertib. HCl
0.5µM – 20µM (Spencer, 2014)44
Met: AMG337
0.1µM – 1.5µM (Du, 2016)45
EGFR: Gefitinib
0.25µM – 20µM (Noro, 2006)46
PKC: Bisindolylmaleimide I
0.5µM – 8.0µM (Sigma)
PDK1: GSK2334470
0.5µM – 20µM (Yang, 2017)47
2.3. Cell Proliferation Assay
The specific concentrations for each kinase inhibitor used in the following experiments
were determined by MTT cell proliferation assay. After determination of IC50 values
(specific for 293T cell line) for each kinase inhibitor, 293T WT cells were seeded in other
96-well plates at same density (1000 cells/100µl/well) 24hrs before treatment with one low
concentration dose and one high concentration dose. The concentrations of each kinase
inhibitor were chosen based on the IC50 values and previous studies. The cells were
analyzed after 72hrs exposure. The experiments conducted in triplicate sets and assessed
by ANOVA with Tukey’s Multiple Comparisons test with the p – value < 0.05 considered
significant.
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Table 2. Dosing Concentrations
Inhibitor
PI3K: Buparlisib (BKM120)
(Anderson, 2015)48
Mek: GSK1120212 (Abe,
2011)49
Akt: Afuresertib. HCl (Yamaji,
2017)50
Met: AMG337 (Du, 2016)45
EGFR: Gefitinib (Khalil,
2017)51
PKC: Bisindolylmaleimide I
(Ingeborg, 1999)52
PDK1: GSK2334470

Dose 1 (Low Concentration)
0.1µM

Dose 2 (High Concentration)
0.25µM

0.5nM

2.0nM

1.0µM

3.0µM

0.1µM
0.25µM

0.3µM
0.5µM

0.5µM

2.0 µM

1.0µM

3.0µM

2.4. Cisplatin and Kinase Inhibitor Combination Assay
293T cells were seeded in 96-well plates at a density of 1000 cells/100µl/well 24hrs before
treatment with different inhibitors at specific cisplatin concentrations range. The
concentrations of each kinase inhibitors were maintained whereas, and the concentration
range for cisplatin was from 1.0µM to 100µM. The cells were analyzed after 72hrs
exposure, and the dose-response curves were generated in GraphPad Prism 7 (GraphPad
Software Inc. La Jolla, CA, USA).
3.   Western Blot
80-90% confluent 293T cells were starved in media without serum overnight. Next
morning, several kinase inhibitors were added for one hour prior to stimulation by the
addition of FBS to a final concentration of 10%. Cells were harvested 30 minutes later and
lysed in RIPA buffer with protease and phosphatase inhibitor (Halt from ThermoFisher).
The Bradford Protein Assay (BioRad, Hercules, California) was used to determine the
protein content of each sample. Treated lysates were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), and then transferred to nitrocellulose
membranes (BioRad) for 2 hours at 100 V with the electrophoretic tank transfer apparatus
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(Bio-Rad). The membranes were then blocked with 5% nonfat milk in TBST buffer (20mM
Tris-HCl pH7.4, 150mM NaCl and 0.05% (v/v) Tween-20) and probed with primary
antibodies overnight at 4°C. The primary antibody used in this experiment was anti hPhospho-p70 S6 Kinase (Cell Signaling Technology #9205) in 1: 1000 dilution with
TBST buffer. The membrane was then detected by the secondary label antibody or
secondary antibody with an enzyme such as horseradish peroxidase that is detected by the
signal it produces corresponding to the position of the target protein. Finally, the signals
were captured on a film that developed in a dark room (Mahmood, 2012)62. Multiple film
exposures were made by using chemiluminescence substrates (ThermoFisher Scientific,
NJ), which enables optimization of signal to noise. The quantification of the Western Blot
was conducted by ImageJ and GraphPad Prism 7 (GraphPad Software Inc. La Jolla, CA,
USA).
4.   DR-GFP Homologous Recombination Assay
DSB recombination reporter pDR-GFP and I-SceI endonuclease expression vector
pCBASceI were generated following standard protocols (QIAGEN Plasmid Maxi Kit)53.
The 293T stable cell lines were established by transfecting with DR-GFP plasmid. After
plating these transfected cells overnight, a plasmid harboring I – Sce (pCBASceI) was
transfected by lipofectamine 3000, and selective inhibitors were added 2 to 4 hours posttransfection. The number of GFP positive cells were counted and analyzed by flow
cytometry and quantified as a percentage of total cells. All doses were set up in triplicate
and experiments were repeated in three times to yield consistent and reproductive results.
Fisher’s exact test and ANOVA with Tukey’s Multiple Comparisons test assessed the
results with p-value < 0.05 considered significant
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IV.  

Results

Effect of Kinase Inhibitors on Cells Growth In Vitro
All the kinase inhibitors chosen in this experiment have been studied extensively, and FDA
approval has been obtained for Trametinib and Gefitinib, for cancer treatment. The rest of
the inhibitors have also been clinically tested. MTT assays verify the ability of each
inhibitor in suppressing cell proliferation with 293T cells. The IC50 values of each kinase
inhibitor for 293T cell line, as calculated by MTT assay and GraphPad Prism 7 (Sebaugh,
2011), are summarized in Figure 10. 293T cells are highly-sensitive to buparlisib [IC50 < 1
µmol/L], less sensitive to GSK1120212, and Bisindolylmaleimide I [1µmol/L < IC50 <
10µmol/L], and least sensitive to Afuresertib , AMG337, Gefitinib and GSK2334470 [IC50 >
10 µmol/L]
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Figure 10. IC50 values for 293T cell lines using the MTT assay.
For 293T cell lines, the IC50 value for BKM120 (PI3K inhibitor) is 0.91µM, for GSK1120212 (Mek
Inhibitor) is 5.17nM, for Afuresertib (Akt inhibitor) is around 20.33µM, for AMG337 (Met
inhibitor) is 26.61µM, for Gefitinib （ EGFR inhibitor) is 10.7 to 20.45µM, for
Bisindolylmaleimide I (PKC inhibitor) is 2.75 to 4.58µM, and for GSK2334470 (PDK1 inhibitor)
is above 100µM
Highly-sensitive: buparlisib [IC50 < 1 µmol/L]
Intermediate-sensitive: GSK1120212 [1nmol/L < IC50 < 10nmol/L], and Bisindolylmaleimide I
[1µmol/L < IC50 < 10µmol/L]
Resistant : Gefitinib, Afuresertib, AMG337, and GSK2334470[IC50 > 10 µmol/L]
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For this experiment, the ultimate goal is to investigate the effect of each inhibitor on HR
of DSBs. The concentrations of each kinase inhibitor chosen in this thesis should exhibit
robust inhibition of its cognate target without inhibition of cell proliferation. Two
concentrations for each inhibitor were chosen to show the minimal impact on cell growth
in our IC50 characterization process. These concentrations have also been investigated for
the ability to inhibit each respective kinase. The impact of these chosen inhibitor
concentrations was further analyzed by MTT assay. These data demonstrated that for PI3K,
Mek, Akt, Met, and EGFR kinase inhibitors, there exist no significant difference between
controls with low and high concentration dosing groups, while for PKC and PDK1 kinase
inhibitor, the high concentration treatments slightly inhibit cell growth (Figure 11).
However, based on the results from ANOVA with Tukey’s multiple comparisons, for PKC
and PDK1 kinase inhibitor, since the high concentration treatments have no significant
difference with low concentration treatments, the adjusted P values for these two tests are
only slightly smaller than 0.05 (0.04 for PDK1 and 0.01 for PKC), and there are only three
test groups for each treatment, therefore, some statistic deviations might exist. More
important,

the

high

concentration

dose

is

chosen

below

IC50

values

for

Bisindolylmaleimide I and GSK2334470. In the following experiments, all 293T cell lines
are treated with high concentration dose.
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Figure 11. Impact of Chosen Inhibitor Concentrations on 293T cell proliferation.
Both IC50 values and cell viability for each treatment group are analyzed by the MTT Assay. All
collected data are then processed by ANOVA with Tukey’s Multiple Comparisons test with p value
< 0.05 considered significant.

The inhibitors suppress activity of kinases while the cell growth conditions are not
affected.
The inhibitors chosen in this thesis mainly affected two pathways, the MAP kinase, and
PI3 kinase cell signaling pathway, and there are significant overlaps as well as crosscommunications between them. However, inhibitors for downstream kinase substrates still
possess unique responses. The activation of ribosomal protein S6 kinase beta-1 (S6K1) was
used as the first readout. Though the phosphorylation of Thr229 on p70S6K (mainly by
PDK-1) is activated by signals that can also activate the PI3K pathway, there exist other
phosphorylation sites on p70S6K aside from Thr229.
293T cells were firstly serum-starved for 24 hours, and the cells were incubated with
respective inhibitors for one hour. Then FBS was added to a final content of 10% for 30
minutes before harvest and lysis. The cell lysates were analyzed for p70S6K
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phosphorylation by Western blot analysis. Western Blot bands were quantified via ImageJ,
and the results were plotted by GraphPad Prism 7 (Figure 12).

Figure 12. Western Blot Analyses: Effect of Kinase Inhibitors on p70S6K
phosphorylation in 293T cells
The lanes from left to right, the sequence of bands is: Control, BKM120 (for PI3K), GSK1120212
(for Mek), Afuresertib (for Akt), AMG337 (for Met), Gefitinib (for EGFR), Bisindolylmaleimide
I (for PKC), and GSK2334470 (for PDK). The bottom two bands correspond to two isoforms of
p70S6K. Mouse vinculin antibody was used for loading control.
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Three of the inhibitors display significant inhibition of p70S6K phosphorylation in 293T
cells: 0.25µM BKM120, 2.0nM GSK1120212, and 3.0µM GSK2334470. Interestingly, the
phosphorylation of p70S6K on Thr229 seemed to be elevated by the AKT inhibitor, which
requires further investigation. On the other hand, though PI3K pathway is downstream of
the majority of receptor kinases, neither Met inhibitor nor EHFR inhibitor showed
significant inhibition of p70S6K phosphorylation, since the growth factor rich media with
10% FBS will inevitably activate PI3 kinase pathway (Figure 12).

PI3K/Akt/PDK/mTOR pathway suppress the Homologous Recombination Repair in
293T cells
To detect DSB-induced HR, DR-GFP reporter was transfected to 293T wild type cells
using LipofectAMINE 3000 (Invitrogen), and stably transfected 293T – DR cell line is
produced by the selection with puromycin – resistance (1.5µg/ml). Two differentially
mutated GFP genes oriented as direct repeats composes DR-GFP reporter: the recognition
site for the rare-cutting I-SceI endonuclease is in upstream repeat, while a 5’ and 3’
truncated GFP fragment is located in the downstream repeat. DSB in the upstream GFP
gene is caused by transient expression of I-SceI and HR repair results in GFP+ cells (Figure
13.a), which can be visualized and imaged by fluorescence microscopy (Figure 13.b) and
quantified by flow cytometry. In this thesis, the number of GFP positive cells in each
sample represents the efficiency of HR.
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(a)

(b)

Figure 13. Design of HR Assay.
(a) To analyze the impact of different signaling pathways, a 293T cell lines stably transfected with
DR-GFP plasmid was established. After plating these cells overnight, a plasmid harboring I-Sec
(pCBASceI) is transfected by lipofectamine 3000. Selective inhibitors were added 2 to 4 hours
post-transfection. Percentage of fluorescent cells was analyzed by flow cytometry and quantified
as a percentage of total cells. (b) GFP+ cells can be visualized and imaged by fluorescent
microscope. The example in this figure is from PI3K treatment group.
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GFP+ cells quantifications are processed by flow cytometry, and the raw data is then
analyzed via Fisher’s exact test and Unpaired T-test with the p-value < 0.05 considered
significant (Figure 14, 15). For Chi-Square test or Fisher’s exact test, p values are
calculated based on the total number of cells, while in unpaired T-test, p values are
generated by the comparisons the percentage of GFP positive cells in control group with
other treatment groups (Figure 16). Chi-Square reveals whether there is a relationship
between two treatments and T-test is used to test whether the difference between two means
is zero.
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Figure 14. Impact of Inhibitors on HR Repair of DSBs (T Test).
Using sub-lethal concentrations of each inhibitor, their respective impacts on homologous
recombination repair of DSBs were analyzed by the DR – GFP assay following the protocol in
Figure 13(a). Numbers of GFP positive cells in each treatment group are compared with numbers
in control groups and p values are calculated via ANOVA with Tukey’s Multiple Comparisons test.
Any p values less than 0.05 is considered statistically significant. Data summarized in ** represents
very significant with p values between 0.001 to 0.01, in * represents significant with p values
between 0.01 to 0.05.
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Figure 15. HR Repair is regulated by several cell signaling pathway (Chi-Square).
Numbers of GFP positive cells in each treatment group are compared with numbers in control
groups and p values are calculated via Fisher’s exact test. Any p values less than 0.05 is considered
statistically significant. Data summarized in **** indicates extremely significant difference with p
values less than 0.0001: ** represents very significant with p values between 0.001 to 0.01. More
detailed results are shown in Figure 16. Figure 14, 15 and 16 present data from 1.22 trial.
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Figure 16. Detailed Statistic Analysis for kinase inhibitor suppressed HR.
P values are calculated from Fisher’s Exact test (Chi – Square) and Unpaired T - Test
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Collectively, these results indicate that inhibition of PI3K directly or its downstream
pathway (Akt and PDK) compromise homologous recombination repair of DSBs. These
effects are reproducible with a different batch of cells, and consistent with the earlier report
that mTOR could regulate HR (Chen, 2011). Therefore, it could be inferred that
PI3K/Akt/PDK/mTOR cascade regulates the mechanisms of homologous recombination
for DSBs.

Effects of MAPK/ERK or Mek pathway to homologous recombination
Trametinib (GSK1120212) was used to investigate the impact of MAP kinase pathway on
HR repair. It was suggested that the inhibition of the Mek (also known as MAPK/ERK) or
Glycogen synthase kinase 2 (GSK3β), which is regulated by Mek pathway and respond to
glucose, might enhance homologous recombination efficiencies in cells (Lin, 2014).
However, current results from this experiment demonstrate the inhibition of this pathway
has minimal, if any, impact on HR repair of DSBs. The experiments were repeated four
times independently, each time with triplicates. No significant numerically or biologically
differences exist between control and experimental groups even if numerically substantial
(Figure 17).
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Figure 17. Mek Inhibitor GSK1120212 affects HR Efficiency significantly
Any p values less than 0.05 is considered statistically significant. Data summarized in ****
indicates extremely significant difference with p values less than 0.0001.

Regulation of DSB repair in HR via Growth Factors (Epidermal growth factor EGF,
Hepatocyte growth factor HGF
PI3K pathway is activated by myriad of pro-growth and/pro survival factors, especially
these that activate receptor tyrosine kinases, which include epidermal growth factor (EGF),
vascular endothelial growth factor (VEGF), fibroblast growth factors (FGF), insulin,
platelet-derived growth factors (PDGF), hepatocyte growth factor (HGF), and many others.
In 293T cells, the expression of EGF receptor is minimal and 293T cells display minimal
response to EGF stimulation. On the other hand, 293T cells express significant HGF
receptor, c-Met, and is generally response to HGF stimulation for subsequent PI3K
activation is the absence of serum (Viticchie, 2015). Met is a receptor tyrosine kinase that
can activate a wide range of different cellular signaling pathways after binding with its
ligand, HGF, which acts as a pleiotropic factor and cytokine to promote cell proliferation,
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survival, motility, scattering, differentiation, and morphogenesis (Organ, 2011). EGFR is
a transmembrane protein that functions as the receptor for members of the EGF family of
extracellular protein ligands. We first tested EGF, in general as a negative control, for any
potential effect of growth factors on HR. In this experiment, we added 100 ng/ml EGF
post-transfection in the presence of 10% FBS, which could further complicate the situation
as FBS contains variety of growth factors. Our assay indicates EGF had minimal impact
on HR with numerically less than 10% reduction while statistically significant (Figure 17).
The effects of other growth factors including HGF are planned.
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Figure 18. Addition of EGF did not increase the efficiency of HR in 293T cells.
Any p values less than 0.05 is considered statistically significant and summarized in *.

The Effect of PKC Inhibitor
Though the statistical analyses show that the inhibition of PKC kinase even increases the
efficiency of HR significantly, the results might be confounded by the overlap between
orange and green color because the PKC inhibitor possesses bright orange color, which
could complicate the fluorescence flow cytometric analysis. While the observation that
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Figure 19. Ratio of “GFP positive cells” in 293T wild type cells.
293T wild type cells were treated with 2.0 µM of Bisindolylmaleimide I overnight, and the number
of green cells is counted by flow cytometry. Since no DR and I-SceI plasmids were transfected,
theoretically, non GFP positive cells should exist in wild type sample. The conflict result might
indicate the problem exists in the choice of kinase inhibitor.

Cellular Decisions to Cisplatin – Induced DNA Damage
Platinum derivatives such as cis-Diaminedichloroplatinum (II) (Cisplatin), are a class of
potent chemotherapeutic agents that treats a variety of cancers for decades (Sears, 2012).
As the primary biological target of cisplatin, N7 position of purine bases in DNA molecule
forms covalent bonds with the platinum atom of cisplatin. 1,2- or 1,3- intra-strand adducts
Administrator
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and a lower percentage of inter-strand adducts are then formed, distorting of DNA double
helix, which interferes with DNA replication and transcription. The cellular proteins that
can recognize this alteration in the DNA structure are used to repair cisplatin-induced DNA
damage (Basu, 2010). However, resistance development is the most significant challenge
for cisplatin application. It has been reported that up-regulation of homologous
recombination or translesion synthesis play critical roles in cisplatin resistance (Aloyz,
2002). If HR plays a significant role in DNA damage repair caused by cisplatin, then
inhibition of HR by kinase inhibitors could enhance its toxicity. We conducted the
combination studies on 293T cells.
WT – 293T cells were treated in combination of cisplatin and kinase inhibitors. Though
the results are preliminary, some interesting conclusions can be drawn. The dose-response
curves suggested that protein kinases regulated the cellular responses to cisplatin-induced
DNA damage. With the addition of kinase inhibitors, 293T cells are more sensitive to
cisplatin (Figure 20, 21), and three of kinases have been identified that they can regulate
cellular decisions to repair DSBs in homologous recombination pathway (Figure 14, 15).
More specifically, first, these inhibitors that showed no impact on HR, including against
EGFR, MET, and MEK, have no effect on cisplatin toxicity. Second, inhibitors that affect
HR, including against PI3K, AKT, and PDK, all display moderate enhancement of cisplatin
toxicity. Third, PKC inhibitor, though displayed no impact on HR, showed the strongest
enhancement of cisplatin toxicity. One possible explanation is the fact that PKC is critical
for regulating Pol h activity (Peddu, 2018). Now we are in the process to investigate
whether the downstream cellular effects of cisplatin treatment have an impact on HR
catalyzed repair of a non-cisplatin-damaged DSBs.
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Figure 20. Cell Survival Assay for the Combination of Cisplatin and Kinase Inhibitor
WT-293T cells were incubated with cisplatin and kinase inhibitors for 72 hours. The concentrations
of each kinase inhibitors were maintained (High Concentration Listed in Table 2) whereas, and the
concentration range for cisplatin was from 1.0µM to 100µM. More details are shown in Figure 21.
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Figure 21. More Detailed IC50 curves and Dose-Response Curves for the Cell
Survival Assay for the Combination of Cisplatin and Kinase Inhibitors.
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V.  

Discussion

i.  

Cellular Decision to Repair DSBs by Homologous Recombination is
regulated by cytoplasm signaling event.

The concentrations of each kinase inhibitor used in this experiment should suppress the
phosphorylation status for a specific kinase substrate but not inhibit cell growth. The sublethal concentrations of each inhibitor are determined by IC50 curves (Figure 10) and cell
proliferation assay (Figure 11) so that each will have a minimal impact on cell proliferation.
To avoid possible bias, the 293T cells in the presence of two different concentrations of
each inhibitor for a similar time-frame as DR-GFP assay. Western Blot analysis was
conducted to ensure that the inhibitor concentrations employed have a significant impact
on respective signaling pathways. First, phosphorylation of S6K (p70S6K) was selected as
the initial readout of activation of PI3K pathways. S6 kinase beta-1 (S6K1), a
serine/threonine kinase, acts downstream of PI3 kinase pathway (Figure 22), and are targets
of Akt, PDK1 (Figure 22), and Mek (Figure 25). Since Akt and PDK1 are activated and
phosphorylated by the activation of PI3K (Figure 22), therefore, the antibody of S6K used
in this experiment can indicate the effect on signal transduction for the inhibition of PI3,
Akt and PDK1 kinases (Figure 12). The selected antibody MAB8964 (Cell Signaling) is
targeted against phosphorylation of T229, a direct target of PDK. The results indicate that
0.25 µM BKM120, 2.0 nM GSK1120212, and 3.0 µM GSK2334470 inhibited the
phosphorylation on T229 of S6K. It is interesting to note that inhibition of AKT increased
the phosphorylation of T229, the direct target of PDK. We plan to use other antibodies for
the detection of other potential phosphorylation sites, especially direct targets of AKT and
mTor. Nevertheless, the inter-relationship between Akt and PDK1 is under-explored. One
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possibility is that Akt is phosphorylated and activated by PDK1, the blocking of Akt
pathway might not influence PDK1 pathway (Figure 22). Thus, with the addition of Akt
inhibitors, S6K can still be phosphorylated by PDK1, which might cause the increase signal
detected by Western Blot. Met and EGFR act as the high-affinity tyrosine kinase receptor
for hepatocyte growth factor (HGF) and epidermal growth factor (EGF). Though both Met
and EGFR are up-stream of the PI3K - Akt pathway, the activation of PI3 kinase is not
only depended on the Met or EGFR. Therefore, to detect the effect on signal transduction
by the addition of Met or EGFR inhibitor, the specific antibody for kinase receptor itself
should be used. Since S6K is not involved in the downstream pathway for PKC kinase,
another specific antibody for phosphorylated PKC kinase will be used in the future to
improve this experiment.
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Figure 22. Extracellular Cell Signaling Pathway have Impact on Cellular Decision for
DNA Repair.
These factors transduce signals through cytoplasmic kinase cascades to affect the decision of
whether to repair a DSB.

DSB – induced HR was measured by DR-GFP reporter in this research. Nakanishi ‘s HRReporter was modified to analyze the impact of different signaling pathways (Nakanishi,
2011). DR-GFP plasmid is transfected in wild type 293T cells. This vector consists two
defective GFP genes: the arrow indicates the I – SceI endonuclease restriction site located
in the first GFP genes and the cells are GFP negative. After generating a stable 293T DR
cell line, I – SceI endonuclease expression vector is then transfected. Cellular expression
of I – SceI causes a DSB and the downstream wild-type GFP sequence now is used as a
template for HR repair, which results in GFP positive cells. Selective inhibitors or growth
factors (EGF) were added 2 to 4 hours post-transfection and percentage of fluorescent cells
was analyzed by flow cytometry and quantified as a percentage. The flow – chart of DRGFP assay is shown in Figure 23.
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Figure 23. Flow – chart of DR-GFP assay with the treatments of Kinase Inhibitor

The cells with transfected DR-GFP plasmid was selected by 1.5µg/ml of puromycin, To
estimate the transfection efficacy of pCBASceI (I-Sec), an internal control vector that
constitutively expressed a reporter protein (GFP in this thesis) was used to estimate the
transfection efficiency for DR – GFP plasmid. This GFP – expressing plasmid had similar
insert size with DR – plasmid and was transfected into a separate well of WT 293T cells.
The fluorescence microscopy image in Figure 24 the appearance of GFP fluorescence from
the living, viable cells (Plasmids 101), and routine transfections all results in 6—80%
efficacy under conditions we used.
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Figure 24. Measure Transfection Efficiency by Internal Control Vector.
The GFP – expressing plasmid used has similar insert size with our test plasmids, DR – GFP and I
- SceI. As a positive control, this internal control vector is used when transfected with DR – GFP
plasmid and I – SceI plasmid. The transfection of internal control vector and test plasmid occurred
at the same time and under same conditions, but in separated wells.

One critical question remains in the assessment of HR defect. There are two factors for the
significant inhibition of HR activity. Granted, all differences have to be statistically
significant. However, a statistically significant difference only indicates that the difference
is unlikely to have occurred by chance, but does not mean the such difference is
biologically large, important, or significant (Dosits.org, 2019). The concept of biological
relevance is explored that before studies are initiated the nature and size of relevant
biological changes or differences is defined, and those pre-defined relevant biological
effect will be used to design studies (EFSA Scientific Committee, 2011). In clinical settings,
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it is observed 16% cutoff in loss of heterozygosity can define the benefit of PARP
inhibition in ovarian cancer treatment (Morgan, 2018).
In our results, the p-values calculated by Fisher’s exact test (Figure 15, 17) demonstrated
that the addition of kinase inhibitors affected the efficiency of HR significantly, these
differences might not be all biologically significant. The activity of PI3K family members
is activated after growth factors and cytokines binding to the transmembrane receptors, and
phosphatidyl-inositol di-phosphate (PIP2) is then phosphorylated to generate PIP3 at the
plasma membrane. PIP3 recruits Akt and PDK1 that containing a pleckstrin homology
(PH) domain to the membrane. When Akt isoform is activated and phosphorylated by
PDK1, the activity of mTOR is then activated, which can regulate HR repair following
DSBs (Liu, 2014). Meanwhile, PI3K activity plays a critical role for Rad51 recruitment
since the inhibition of PI3K decreases Rad51 focus formation (Juvekar, 2012), and Akt1
can stimulate HR repair of DSBs via a Rad51 – dependent manner (Mueck, 2017). Based
on current studies, we can hypothesize that the efficiency of HR would decrease with the
addition of PI3, Akt and PDK kinase inhibitors. The statistics results (Unpaired T-test and
Fisher’s exact test) corroborate the initial hypothesize. For PI3K/Akt/PDK1 pathway, a
statistically significant difference means biologically important.
The activation of mitogenic MAP/ERK kinase or Ras – Raf – MEK – ERK pathway
showed minimal impact on HR activity in our assays. Epidermal growth factor receptor
(EGFR), a receptor – linked tyrosine kinase, is activated by extracellular ligands. The
EGFR becomes phosphorylated on tyrosine residues, which provides the binding site for
the SH2 domain of the GRB2 docking proteins. Guanine nucleotide exchange factor SOS
binds the SH3 domain of GRB2. SOS is activated when the GRB2 – SOS complex docs to
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the phosphorylated EGFR, and activated SOS promotes the removal of GFP from Ras. Ras
binds to GTP and become active, which then activate the protein kinase activity of Raf
kinase. Mek is phosphorylated and activated by RAF kinase, and mitogen-activated protein
kinase (MAPK) is activated and phosphorylated by Mek (Figure 25).
Attempts to investigate the impact of MAPK on HR activity by other research groups
produced mixed results. The existence of multiple MAPK pathways further complicates
potential results interpretation. Human ERK1/2 is phosphorylated at Tyr204/187 then
Thr202/185 by Mek1/2, and it catalyzes the phosphorylation of cytoplasmic and nuclear
substrates including transcription factors (Roskoski, 2012). Similar to other MAP kinases,
the p38 MAP kinase pathway is activated by MAP kinase kinases (MKKs) and exerts a
negative influence on ERK1/2 signaling and therefore, HR repair (Golding, 2007). Though
in MAPK/ERK pathway, ERK is a positive regulator for HR repair whereas JNK and p38
have both collaborative and antagonistic effects on cellular response to DSB – induced HR,
the interrelations between them are currently being investigated in more detail.
Our results with Mek inhibitor GSK1120212 were repeated four times independently, each
time with triplicates. GSK1120212 is an allosteric inhibitor of Mek1/2 activity. To inhibit
MEK-Dependent ERK phosphorylation, Mek1/2 activation is inhibited by GSK1120212,
which prevents Raf phosphorylation of Mek on S217 (Gilmartin, 2011). Based on its
properties, we initially hypothesized that the inhibition of Mek kinase would decrease the
efficiency of HR. However, our results showed GSK1120212 did not have consistent
impact on HR (Figure 17). More experiments will be conducted in the future to investigate
the more detailed mechanism that MAPK signaling pathway regulates HR repair.
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Figure 25. Key steps in MAPK/ERK pathway.
Though Mek is not in the downstream pathway of PI3K, since S6K activation is controlled by
insulin – dependent mTOR – mediated phoshphorylation and insulin – independent MAP kinase
(Zhang, 2013), the antibody against phosphorylated S6K can be used to detect the effect on signal
transduction via Mek pathway. Adapted from MAPK/ERK pathway, Wikipedia.

EGFR is involved in several signaling pathways including Ras/Erk and PI3K/Akt, which
might affect the HR repair process. Theoretically, EGFR and its downstream signaling can
affect the intracellular distribution of DNA repair proteins including DNA – PKcs, and
ATM, which are the most upstream kinase for HR repair (Meyn, 2009). As a competitive
inhibitor, Gefitinib prevents ATP binding to the ATP – binding pocket in the kinase domain
of EGFR. Therefore, both PI3K/Akt and Ras-Raf-Mek-Erk pathways are shut down
(Uchida, 2007). We conjectured gefitinib treatment would suppress HR repair significantly.
The experimental results did not support our assumption, and such statistically significant
differences (Figure 15) did not indicate the real biological relevance. Similary with EGFR,
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c – Met is also a receptor tyrosine kinase that activates a wide range of different cellular
signaling pathways after binding with its ligand, hepatocyte growth factor (HGF) (Organ,
2011). HGF induces c – Met phosphorylation, and activates PI3K/Akt signaling pathway
(Usatyuk, 2014). The activation of Ras/Erk or PI3K/Akt pathway is not only dependent on
the activated EGFR or c - Met and the fetal bovine serum used in cell culture media
contains lots of other embryonic growth promoting factors that can also stimulate PI3K/Akt
and MAPK signaling pathway. The results from Western Blot (Figure 12) also indicates
that the S6K pathway is still at least partially activated. Therefore, the function of Met and
EGFR in HR repair cannot be determined yet.
Since the EGF activates the PI3K – Akt cascade signaling pathway, which regulates HR
repair, the efficiency of HR is supposed to increase after incubating with EGF. The
transfected 293T cells were incubated with 100ng/ml of EGF, but the ratio of GFP positive
cells did not increase (Figure 18). One of the possible reasons is 293T cell line does not
highly express the wild type EGFR gene since the number of binding sites of EGFR is only
0.01 × 106 (Derer, 2012). To improve specificity and sensitivity for screening drugs
targeted to EGFR, the A431 cell line, which highly expresses EGFR and largely depends
on the EGFR/MAPK pathway, should replace with 293T cell line (Zhang, 2010).
ii.  

Conclusion and Future Direction

1.   Improvements in the Future
Experiments employing specific antibodies against EGFR and Met should be conducted in
the future to gain additional information and insights concerning the roles of the activation
of Met and EGFR play in the modulation of HR in293T cells. Similarly, it is noteworthy
that the phospho-p70S6 kinase antibody only detects endogenous levels of S6K when
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phosphorylated at Thr421 and Ser424. We are working with a p70S6K antibody that can
detect endogenous levels of total S6K protein. Based on the results from both
phosphorylated S6K and S6K antibodies, we can test whether the phosphorylation of
kinase proteins regulates HR repair. Since S6K is not involved in the downstream pathway
for PKC, the antibodies against phosphorylated PKC and PKC itself should be used in the
future. Furthermore, S6K activation is also controlled by PDK1, which does not require
the activation of Akt. Therefore, instead of using an antibody against S6K, the antibody
against Akt itself might be a better choice in the future.
To detect the effects of growth factor in HR pathway, the serum – and phenol red - free
cell culture media should be used instead of the media with 10% of FBS because growth
factor rich media with 10% FBS will inevitably activate PI3 kinase or MAP kinase pathway,
which will interfere with the final results. For the choice of PKC inhibitor, if we
continuously work with bisindolylmaleimide I that contains bright orange color, the
technique named “fluorescence compensation” should be used in flow cytometry to ensure
that the fluorescence detected derives from the fluorochrome that is being measured.
Finally, experiments using a variety of cancer cells should be considered to compare and
contrast HR control, in response to environmental chemicals and synthetic chemicals with
clinical potentials.

2.   Conclusion and Future Direction
Even though additional research is required, our results suggest that there is a
differentiation between PI3K and MAPK pathway in terms of impact on HR. The
activation of mitogenic MAP kinase pathway has minimal impact on HR activity, whereas
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PI3K pathway plays a critical role for cellular decision to repair a DSB by HR. Among the
downstream PI3K pathways, inhibition of Akt and PDK significantly suppresses HR repair.
Though still in early stage, our results (Figure 20, 21) imply that the sub-lethal
concentrations of certain kinase inhibitors could be combined with chemotherapeutic
agents, cisplatin, that cause DSBs for management of cancers. Certain protein kinases
involved in this thesis can regulate the cellular responses to cisplatin-induced DNA damage
that the cells become more sensitive (with lower IC50 values) to cisplatin after adding
kinase inhibitors.
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VI.  

Appendices

A fluorochrome is a fluorescent chemical compound that raises from the ground state to an
excited state when absorbing light, and return to the ground state by the emission of a
quantum of light. In flow cytometry, laser light, which produces light in the UV and visible
range, is used to excite the fluorochromes. Within a flow cytometer, it is possible to
separate combinations of fluorochromes based on the excitation and emission properties of
fluorescent compounds (Sinobiological.com, 2019)58. GFP, a member of the fluorochrome
family, can be attached to other specific proteins to form a fusion protein and then
synthesized in cells after transfection of a plasmid carrier. In this research, mutated GFP
gene is transfected to 293T wild type cells by pDR-GFP reporter, and HR repair corrects
this mutation and results in GFP positive cells, which can be detected and separated by
flow cytometry (Figure 13b). However, energy transfer occurs whereby excitation of one
compound causes the other to fluoresce if two fluorochromes are closely associated and
the acceptor molecule has an absorption spectrum that overlaps with the emission spectrum
of the donor molecule. In that case, the effective emission maximum will be shifted, and
fluorescence from more than one fluorochrome may be detected.
Spectral overlap might cause the great increase in “GFP positive cells” in
bisindolylmaleimide I treatment groups. Since bisindolylmaleimide I is a cell – permeable
inhibitor, its bright orange color might stain 293T cells. The structure of
bisindolylmaleimide I (Figure 10f, 16f) contains two combined aromatic groups with a
delocalized conjugated π system, which can be found in a typical fluorochrome molecule.
When treated 293T wild type cells with bisindolylmaleimide I, after enzymatically
detaching by Trypsin – EDTA solution and washing by phosphate buffered saline (PBS),
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the collected cells still contain orange color. These cells are sorted by flow cytometry using
a green/yellow- green laser, and there exist 1.05% of green cells (Figure 19). Since none
plasmid were transfected to wild type sample, those green cells can be regarded as pseudo
– GFP positive cells and the most possible reason is the color from bisindolylmaleimide I.
Hence, it could be inferred that bisindolylmaleimide I functions as a fluorochrome, which
might also be excited with green laser, or energy transfer might occur between
bisindolylmaleimide I and GFP since they are associated closely and both of two
fluorochromes are detected. Currently, we are working with other colorless PKC inhibitors
to test its roles in the regulation of HR repair.
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